Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$27.2M Buy
75,057
+1,325
+2% +$454K 0.89% 41
2026
Q1
$25.9M Buy
73,732
+72,864
+8,394% +$26M 0.92% 41
2025
Q4
$284K Buy
868
+121
+16% +$38.4K 0.01% 190
2025
Q3
$211K Buy
+747
New +$217K 0.01% 209
2021
Q2
Sell
-1,060
Closed -$264K 58
2021
Q1
$264K Hold
1,060
0.02% 84
2020
Q4
$244K Hold
1,060
0.02% 82
2020
Q3
$269K Buy
1,060
+210
+25% +$52K 0.02% 79
2020
Q2
$200K Buy
+850
New +$194K 0.02% 80

Other funds holding AMGN

Summitry LLC's AMGN Position: Q2 2026 in Review

Summitry LLC increased its Amgen (AMGN) stake by 1.8% in Q2 2026, buying an estimated $454K and bringing the position to 75,057 shares worth $27.2M. The position accounts for 0.89% of the portfolio, ranked #41.

Summitry LLC first reported a position in AMGN in Q2 2020 and has held it in 8 quarters since. 1,221 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Summitry LLC held 75,057 shares of Amgen worth $27.2M as of Q2 2026.
  • Summitry LLC bought 1,325 Amgen shares in Q2 2026, an estimated $454K.
  • Amgen made up 0.89% of Summitry LLC's portfolio in Q2 2026, its #41 holding.
  • Summitry LLC first reported a position in Amgen in Q2 2020 and has held it in 8 quarters since.
  • 1,221 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Summitry LLC's 13F filing for Q2 2026, filed 21 Jul 2026.